S
CVAC

swisspartners’s CureVac CVAC Stock Holding History

swisspartners’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,410
Closed -$219K – 83
2021
Q1 		$219K Buy
+2,410
New +$234K 0.18% 77

Other funds holding CVAC

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

swisspartners's CVAC Position: Q2 2021 in Review

swisspartners sold out of CureVac (CVAC) in Q2 2021, closing a stake of 2,410 shares — an estimated $219K sold.

swisspartners first reported a position in CVAC in Q1 2021 and held it in 1 quarter. The position peaked at $219K in Q1 2021. 109 funds tracked by Wall St. Rank hold CVAC as of Q2 2021.

  • swisspartners reported no remaining CureVac position as of Q2 2021 after selling out during the quarter.
  • swisspartners sold 2,410 CureVac shares in Q2 2021, an estimated $219K.
  • swisspartners first reported a position in CureVac in Q1 2021 and held it in 1 quarter.
  • swisspartners's CureVac position peaked at $219K in Q1 2021.
  • 109 funds tracked by Wall St. Rank held CureVac as of Q2 2021.

Based on swisspartners's 13F filing for Q2 2021, filed 11 Aug 2021.